The online interaction and matchmaking systems of euroPLX Conferences provide 25 to 30 pre-arranged business meetings per attending company. It is the preferred partnering platform for new business opportunities since almost 24 years. Information exchange and interaction between confirmed registrants starts right after registration, intensifying during the month before the conference with two days of targeted, pre-scheduled one-on-one meetings of top executives of drug developing, producing or marketing companies from all over the world.

The partnering scope ranges from prescription to OTC drugs, companion diagnostics, nutraceuticals, and medical devices: development, licensing, marketing, promotion, and distribution. The “Dynamic Partnering Focus” of this conference shows up on this page as soon as a sufficient number of collaboration interests are submitted. In addition, attending companies may offer or look for R&D services, supporting technologies (e.g. new drug delivery), contract manufacture, and the supply of APIs and intermediates.

We’re looking forward to attending this event and hope to see you there!

Additional News

  • 16 April 2026

    Expanding Beyond FDA & EMA: Strengthening Our Global Regulatory Footprint with GCC

    Quinta-Analytica has successfully completed a full on-site GCP inspection within the GCC framework, further strengthening its international regulatory footprint and clinical research credibility.

  • 25 March 2026

    ADC Webinar: DAR, Bioanalysis and Intact MS in Next-Generation ADC Development

    On behalf of Conscio Group, registration is now open for our free expert-led webinar on DAR characterization, bioanalytical strategy and mass spectrometry insight in ADC development.

  • 17 December 2025

    PF 2026: Thank You from Quinta-Analytica

    In 2025, Quinta-Analytica continued to turn complex development challenges into tangible progress. Our PF 2026 message looks back at key milestones and thanks the partners, clients, and teams who made them possible.